Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Orion Corp New B Shs — Q1 2026 Earnings Presentation
15 slides from Orion Oyj Class A's earnings presentation, Apr 23, 2026
Slide 1: Orion Interim Report January-March 2026
Orion Interim Report January-March 2026 23 April 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q1 2026 Highlights
Q1 2026 Highlights • Solid performance across all businesses • Mr. Berkeley Vincent appointed Executive Vice President, Innovative Medicines and a member of Orion Executive Team as of 8 April 2026 • ODM-212 granted orphan drug designation in mesothelioma by FDA • Initiation of TEADCO Phase 1b/2 bask
Slide 4: Q1 2026 Financial highlights
Q1 2026 Financial highlights Net sales, EUR million Operating profit, EUR million Earnings per share, EUR Operating profit margin 27.5% (22.0%) +17.8% +47.3% +47.4% 417.7 114.8 0.64 354.6 77.9 0.44 Q1/2025 Q1/2026 Q1/2025 Q1/2026 Q1/2025 Q1/2026 4 23 April 2026 © Orion Corporation
Slide 5: Net sales bridge (MEUR)
Net sales bridge (MEUR) 1.1 0.6 417.7 5.2 1.9 52.5 1.8 354.6 Q1/2025 1 2 3 4 5 6 Q1/2026 1 Innovative Medicines 4 Animal Health 2 Branded Products 5 Fermion 3 Generics and Consumer Health 6 Translation differences and other operations 5 23 April 2026 © Orion Corporation The figures in the chart are
Slide 6: Operating profit bridge (MEUR)
Operating profit bridge (MEUR) 40.8 -0.6 -0.3 114.8 21.3 -15.0 77.9 -9.3 Q1/2025 1 2 3 4 5 6 Q1/2026 1 Change in sales volume 4 Milestones 2 Changes in prices, COGS, product mix and FX 5 Other operating income and expenses 3 Royalties 6 Fixed costs 6 23 April 2026 © Orion Corporation The figures in
Slide 7: Innovative Medicines
Innovative Medicines +53.6% Nubeqa® sales (MEUR) 150.3 213 5.4 48 166 152 97.8 140 145 48 6.3 36 44 50 144.9 95 92 72 26 165 38 91.5 50 21 116 118 96 95 MEUR 18 69 51 54 32 Q1/2025 Q1/2026 2024 2024 2024 2024 2025 2025 2025 2025 2026 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Nubeqa® Other Royalties Product sales t
Slide 8: Branded Products
Branded Products +6.8% 82.2 77.0 8.2 • Easyhaler® budesonide-formoterol the growth driver for the 7.2 respiratory therapy area 24.0 • Recent changes in treatment guidelines favor the use of 23.4 combination products over monoproducts • Growth momentum for Women’s Health therapy area continues 46.5 5
Slide 9: Generics and Consumer Health
Generics and Consumer Health +1.4% 131.7 133.5 • Steady growth for both generic prescription drugs and 33.3 34.4 consumer health products 98.4 99.2 MEUR Q1/2025 Q1/2026 Generic prescription drugs Consumer Health products 9 23 April 2026 © Orion Corporation
Slide 10: Animal Health
Animal Health +3.3% 36.3 35.2 • The growth came from multiple products and different geographic regions MEUR Q1/2025 Q1/2026 10 23 April 2026 © Orion Corporation
Slide 11: Top products and net sales split in Q1 2026
TOP 10 products and net sales split in Q1 2026 EUR vs. Product or product portfolio million 2025 1. Nubeqa® 144.9 +58.4% 3% 9% 2. Easyhaler® product portfolio 48.3 +7.0% 3. Entacapone products1 21.0 -1.2% 36% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 9.8 +10.9% 5. Divina® series 8.2 +14.9% 32
Slide 12: Orion Pharma's key clinical development pipeline
Orion Pharma’s key clinical development pipeline Invented by Developer(s) Trial/compound Indication Phase I Phase II Phase III ARASTEP (darolutamide) prostate cancer (BCR2) DASL-HiCaP (darolutamide) (Neo-)adjuvant prostate cancer OMAHA-003 (opevesostat) prostate cancer (later-line mCRPC3) OMAHA-004
Slide 13: Sustainability reporting and performance 2025
Sustainability reporting and performance 2025 Orion Pharma publishes its Sustainability statement as a part of the Financial statement documents in accordance with the sustainability reporting requirements of the European Sustainability Reporting Standards (ESRS). Key highlights -13% 4.9 98% 96% Gre
Slide 14: Outlook for 2026
Outlook for 2026 (specified on 23 April 2026) Net sales EUR 1,950 million–EUR 2,100 million Operating profit EUR 600 million–EUR 750 million 14 23 April 2026 © Orion Corporation
Slide 15: Upcoming events
Upcoming events Half-Year Financial Report 1–6/2026 17/7/2026 Interim Report 1–9/2026 28/10/2026 15 23 April 2026 © Orion Corporation